The company was established in North America in United States. The main department of described VC is located in the Rochester.
The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Mayo Clinic Ventures works on 8 percentage points less the average amount of lead investments. Considering the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. The high activity for fund was in 2019.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Mayo Clinic Ventures, startups are often financed by Sanderling Ventures, Thomas, McNerney & Partners, i2E. The meaningful sponsors for the fund in investment in the same round are Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures. In the next rounds fund is usually obtained by Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures.
We also calculated 1 valuable employee in our database.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Torax Medical, Qlaris Bio, Cadence Neuroscience The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
Funds with similar focus
|Furneaux Capital||Boston, Massachusetts, United States|
|Goodwood Capital Fund||Canada, Ontario, Toronto|
|Greater Bay Area Homeland Development Fund||China, Hong Kong, Hong Kong Island|
|Guokun Investment||China, Jiangsu, Nanjing|
|Houde Qianhai Fund||China, Guangdong, Shenzhen|
|Huaqing Capital||China, Guangdong, Shenzhen|
|Javest Investment Fund||Amsterdam, Noord-Holland, The Netherlands|
|Lynx Technology Partners||New York, New York, United States|
|POSCO BioVentures||California, Carlsbad, United States|
|Shenzhenshi Jiruihe Guquan Touzi||China, Guangdong, Shenzhen|
|SINOCHEM GROUP||Beijing, Beijing, China|
|Suzhou Ruiniu||China, Jiangsu, Suzhou|
|Voxx Electronics||Florida, Lake Mary, United States|
|Zongton Capital||China, Shanghai|
Tympany Research Group
|$4M||22 Nov 2021||Galway, Galway, Ireland|
|$50M||03 Jun 2021||California, United States|
|$8M||01 Mar 2021||Kansas City, Missouri, United States|
|$15M||01 Jan 2021||Tel Aviv-Yafo, Tel Aviv District, Israel|
|$61M||15 Dec 2020||Cambridge, Massachusetts, United States|
|$5M||09 Jan 2020||Oklahoma City, Oklahoma, United States|
|$69M||08 Jan 2020||Cambridge, Massachusetts, United States|
|$33M||07 Jan 2020||South San Francisco, California, United States|
|$40M||23 Dec 2019||New York, New York, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.